Inherited Immune Deficiencies
Conditions
Keywords
MUD Transplant, Transplant, AlloPBSC, HLA Matched Transplant, BMT, Congenital Immunodeficiency, Bone Marrow Transplant
Brief summary
This study uses transplantation to treat patients with problems in their immune system. The immune system cells come from the bone marrow where they grow from special cells called stem cells. Giving patients stem cells from someone else may help to cure many patients with certain immune diseases. This is called 'bone marrow transplantation'. This procedure can have side effects that are life-threatening. To try to make transplantation safer we are using lower doses of the medications used in preparing the patient for the transplant. 'Conditioning' treatments are given to patients to create space in their bone marrow. This lets the cells of the donor go into the bone marrow and produce normal immune cells. This study will use lower doses of a drug called busulfan and lower doses of radiation than what are currently being used in other kinds of bone marrow transplantation for other diseases. Another problem that can occur with bone marrow transplantation is 'graft-versus-host disease'. This happens when the cells of the donor attacks different parts of the patient s body. This study will use a medicine called sirolimus instead of the usual medicine, cyclosporine, to prevent graft-versus-host disease. To go onto this study, you must have: 1. A severe immune deficiency, such as chronic granulomatous disease or leukocyte adhesion deficiency. 2. Have problems from the disease that call for stem cell transplantation. 3. You must also be between the ages of 2 and 40 years. Two groups of patients are included in this study: 1. Patients who have a brother or sister that have stem cells that match the patient. This is known as an allogeneic matched sibling transplant. 2. Patients who do not have a matched sibling donor but have a donor that matches in the National Marrow Donor Program. This is know as matched unrelated donor transplantation. Patients will have the following procedures: * To create space in the bone marrow, patients are given two drugs, Campath-1H and busulfan. To prevent the body from getting rid of the donated cells, patients are given sirolimus. On the day before the BMT, patients in the matched unrelated donor group also receive a low-dose of whole-body radiation. This will further improve the chances that the patients body will accept the donor cells. * Patients will get the donor stem cells through an intravenous (IV) line that goes into a vein in their body. The cells make their way to the bone marrow space and slowly refill the marrow over the next several weeks. Patients will usually stay in the hospital for 30 days after the transplant. * For the first 3 months after the transplant, patients are watched closely. The patients will have frequent visits to the clinic. During these visits the patient will have a physical examination and blood tests. The doctor and nurse will also check any symptoms the patient may have. At day 100 after the transplant a sample of bone marrow is taken. * Patients will continue to be followed periodically for at least 5 years after the transplant.
Detailed description
This is an open-label pilot study of HLA-matched allogenic and matched unrelated donor (MUD) hematopoietic stem cell (HSC) transplant (also referred to as peripheral blood stem cell (PBSC) or bone marrow transplant (BMT)) for patients with X-linked severe combined immune deficiency (XSCID). XSCID is caused by mutations in the IL2RG gene encoding the interleukin receptor signaling gamma chain \[gamma c\]). The study population are older children (greater than or equal to 2 years of age) and adults (less than or equal to 40 years of age) who are experiencing deteriorating and/or dysfunctional immunity and any of a constellation of severe or chronic medical problems warranting transplantation. The study is designed to evaluate whether the use of uniquely designed transplant conditioning and graft-versus-host disease (GvHD) prevention regimens achieve sufficient engraftment of donor hematopoietic stem cells (HSCs) to facilitate robust restoration of cellular immunity (T cell/NK cell number and function) including thymic function, and humoral immunity (B cell number and function) while at the same time enhancing tolerance of the donor graft in a fashion that reduces the occurrence of GvHD but not at significantly enhancing the risk of post-transplant virus infection. One target population are XSCID patients who received matched sibling or haploidentical lymphocyte-depleted transplants as infants with little or no myeloid conditioning, resulting in variable restoration of T cell immunity, but little or no restoration of NK or B cell immunity. Another target population are XSCID patients with partial production or function of gamma c or XSCID patients with clonal somatic reversion of the mutation in the IL2RG gene, who have less severe immune deficiency in childhood. A subset of patients from all of these target XSCID populations may experience progressive deterioration of immune function leading to acute and chronic medical problems that warrant consideration of allogeneic or MUD transplant to restore immunity. The conditioning and GvHD prevention regimens for this HSC transplant protocol are designed to use mobilized peripheral blood stem cells (PBSC) or bone marrow (BM) (if mobilization is not possible) from either an HLA-matched related sibling donor (alloPBSC) as first choice or from an HLA matched unrelated donor (MUD) for those without an appropriate HLA-matched related sibling donor. If there is no appropriately matched sibling donor nor MUD adult donor available, then an appropriately matched cord blood from the cord blood registries may be used for small children XSCID recipients. For the alloPBSC (or alloBM) transplantation (referred to as Group 1), we propose using a busulfan-based, nonmyeloablative conditioning regimen combined with horse Anti-human Thymocyte Globulin (h-ATG) immune suppression conditioning plus post-transplant sirolimus for tolerance inducing immunosuppressant to prevent GvHD. For the MUD or unrelated cord blood transplantation (referred to as Group 2), we will use a similar conditioning regimen, with a few modifications that include addition of total body irradiation with shielding and reduction in busulfan dosing, changes designed to address the increased risk of graft rejection with HLA-matched but unrelated donor HSC.
Interventions
DRUGCampath 1H
Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
DRUGBusulfan
Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
DRUGHorse Anti-human Thymocyte Globulin (h-ATG)
Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
DRUGTotal Body Irradiation (TBI)
TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
DRUGSirolimus or equivalent based on response
post Transplantation immunosuppressants
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: PATIENTS (RECIPIENT) * Must have confirmed genetic diagnosis of XSCID (common gamma chain disorder) by identification of a mutation in the IL2RG gene or by demonstrating failure to detect gamma c protein in patient immune blood cells. * Must have sufficient complications from underlying disease to warrant undergoing transplantation as defined as follows:. Clinical Criteria: (greater than or equal to 1 must be present) i. Infections (not including molluscum, warts or mucocutaneous candidiasis; see vii and viii below): 3 significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criteria. Infections are defined as an objective sign of infection (fever \>38.30C \[1010F\] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician's intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.) 1. Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics . 14 days OR 2. Hospitalization of any duration for infection OR 3. Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection ii. Chronic pulmonary disease as defined by: 1. Bronchiectasis by x-ray computerized tomography OR 2. Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is . 60% of Predicted for Age OR 3. Pulse oximetry . 94% in room air (if patient is too young to comply with performance of PFTs). iii. Gastrointestinal enteropathy: 1. Diarrhea-watery stools . 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above) OR 2. Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated) OR 3. Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level). iv. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition. v. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality. vi. Failure to grow in height: . 3rd percentile for age vii. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are 3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts) viii. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion) ix. Hypogammaglobulinemia: requires regular IgG supplementation Ages 2 years 40 years. HLA-matched family donor available or an HLA matched unrelated PBSC graft (10/10 or 9/10 mismatch) available, or a minimum of 4/6 HLA matched cord blood product. (If the size of the cord blood graft is less than 3.0 x 10(7) cells, a second appropriate 4/6 or greater match cord blood product must be available). Must be HIV negative. Must be able to stay within one hour s travel of the NIH for the first 3 months after transplantation and have a family member or other designated companion to stay with during the post transplant period. Must provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance to NIH -200 NIH Durable Power of Attorney for Health Care Decision Making. If of child-bearing potential, must agree to consistently use contraception throughout study participation and for 3 months post-study. Acceptable forms of contraception are: * Condoms, male or female, with or without a spermicide * Diaphragm or cervical cap with spermicide * Intrauterine device * Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA-approved contraceptive method * Male partner has previously undergone a vasectomy
Exclusion criteria
PATIENT (RECIPIENT) * Eastern Cooperative Oncology Group (ECOG) or equivalent performance status of 3 or more (See Supportive Care guidelines, available at http://intranettst2.cc.nih.gov/bmt/clinicalcare). * Left ventricular ejection fraction less than 40%. * Transaminases greater than 5 times upper limit of normal based on the patient s clinical situation and at the discretion of the investigator. * Liver alkaline phosphatase \>10x upper limit of normal based on the patient's clinical situation and at the discretion of the investigator * Psychiatric disorder or mental deficiency severe enough as to make compliance with the BMT treatment unlikely, and/or making informed consent impossible. * Major anticipated illness or organ failure incompatible with survival from AlloPBSC, MUD or unrelated cord blood transplant * Pregnant or lactating. * HIV positive. * Uncontrolled seizure disorder.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stem Cell Transplant Engraftment | 1 year | Engraftment of allogeneic or matched unrelated (including cord blood) hematopoietic progenitor cells using moderate-dose busulfan and Campath-1H with or without whole body irradiation so as to attain phenotypic correction of congenital immunodeficiencies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Established Stable Mixed Chimerism | 1 year | Number of participants with myeloid chimerism of greater than 10% of donor cells at 1 year post transplant |
| Days to CD3 Count Greater Than 100 u/L | 1 year | Rapidity of immune reconstitution based on number of days to CD3 count greater than 100 u/L. |
| Days to Absolute Neutrophil Recovery (ANC) | 1 year | Recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109 /L (500/mm3 ) for three consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 109 /L. |
| Engraftment Without Development of GVHD | 1 year | Participants who achieved engraftment without development of graft versus host disease (GVHD). |
| Days to Platelet Recovery | 1 year | Platelet recovery is defined as platelet value ≥ 20 × 109/L for three consecutive days and no platelet transfusions administered for previous seven consecutive days. The date of platelet recovery is the date of the first of three consecutive laboratory values ≥ 20 × 109/L. |
| Incidence of Cytomegalovirus (CMV) Disease | 1 year | Number of events of Cytomegalovirus disease based on clinical sequelae that requires treatment (not reactivation) |
| Number of RBC Transfusions Per Subject | 1 year | Average number of red blood cell (RBC) transfusion per subject |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Matched Related Donor Stem Cell Transplant Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 10 mg/kg total dose given intravenously over 2 days | 7 |
| Matched Unrelated Donor Stem Cell Transplant Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day | 36 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) Conditioning with ATG 40 mg/kg total dose over 4 days IV, Busulfan 5 mg/kg total dose over 2 days IV, and TBI 300 cGy in two fractions at day -2 | 3 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day | 2 |
| Total | 48 |
Baseline characteristics
| Characteristic | Matched Unrelated Donor Stem Cell Transplant | Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Matched Related Donor Stem Cell Transplant | Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 23 Participants | 3 Participants | 3 Participants | 2 Participants | 31 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants | 0 Participants | 4 Participants | 0 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 32 Participants | 3 Participants | 7 Participants | 1 Participants | 43 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 0 Participants | 2 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 30 Participants | 3 Participants | 5 Participants | 0 Participants | 38 Participants |
| Sex: Female, Male Female | 3 Participants | 0 Participants | 2 Participants | 0 Participants | 5 Participants |
| Sex: Female, Male Male | 33 Participants | 3 Participants | 5 Participants | 2 Participants | 43 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 9 / 36 | 1 / 3 | 0 / 2 |
| other Total, other adverse events | 3 / 7 | 17 / 36 | 1 / 3 | 2 / 2 |
| serious Total, serious adverse events | 1 / 7 | 4 / 36 | 0 / 3 | 0 / 2 |
Outcome results
Primary
Stem Cell Transplant Engraftment
Engraftment of allogeneic or matched unrelated (including cord blood) hematopoietic progenitor cells using moderate-dose busulfan and Campath-1H with or without whole body irradiation so as to attain phenotypic correction of congenital immunodeficiencies.
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Matched Related Donor Stem Cell Transplant | Stem Cell Transplant Engraftment | 7 Participants |
| Matched Unrelated Donor Stem Cell Transplant | Stem Cell Transplant Engraftment | 31 Participants |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Stem Cell Transplant Engraftment | 3 Participants |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Stem Cell Transplant Engraftment | 0 Participants |
Secondary
Days to Absolute Neutrophil Recovery (ANC)
Recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 109 /L (500/mm3 ) for three consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 109 /L.
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Matched Related Donor Stem Cell Transplant | Days to Absolute Neutrophil Recovery (ANC) | 19.42 Days | Standard Deviation 4.57 |
| Matched Unrelated Donor Stem Cell Transplant | Days to Absolute Neutrophil Recovery (ANC) | 77.44 Days | Standard Deviation 192.34 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Days to Absolute Neutrophil Recovery (ANC) | 25.5 Days | Standard Deviation 15.88 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Days to Absolute Neutrophil Recovery (ANC) | NA Days | — |
Secondary
Days to CD3 Count Greater Than 100 u/L
Rapidity of immune reconstitution based on number of days to CD3 count greater than 100 u/L.
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Matched Related Donor Stem Cell Transplant | Days to CD3 Count Greater Than 100 u/L | 355 Days | Standard Deviation 201.8 |
| Matched Unrelated Donor Stem Cell Transplant | Days to CD3 Count Greater Than 100 u/L | 284 Days | Standard Deviation 296.64 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Days to CD3 Count Greater Than 100 u/L | 16 Days | Standard Deviation 3.46 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Days to CD3 Count Greater Than 100 u/L | NA Days | — |
Secondary
Days to Platelet Recovery
Platelet recovery is defined as platelet value ≥ 20 × 109/L for three consecutive days and no platelet transfusions administered for previous seven consecutive days. The date of platelet recovery is the date of the first of three consecutive laboratory values ≥ 20 × 109/L.
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Matched Related Donor Stem Cell Transplant | Days to Platelet Recovery | 31 Days | Standard Deviation 20.21 |
| Matched Unrelated Donor Stem Cell Transplant | Days to Platelet Recovery | 31.9 Days | Standard Deviation 30.48 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Days to Platelet Recovery | 32.6 Days | Standard Deviation 20.31 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Days to Platelet Recovery | NA Days | — |
Secondary
Engraftment Without Development of GVHD
Participants who achieved engraftment without development of graft versus host disease (GVHD).
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Matched Related Donor Stem Cell Transplant | Engraftment Without Development of GVHD | 6 Participants |
| Matched Unrelated Donor Stem Cell Transplant | Engraftment Without Development of GVHD | 30 Participants |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Engraftment Without Development of GVHD | 3 Participants |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Engraftment Without Development of GVHD | NA Participants |
Secondary
Incidence of Cytomegalovirus (CMV) Disease
Number of events of Cytomegalovirus disease based on clinical sequelae that requires treatment (not reactivation)
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Matched Related Donor Stem Cell Transplant | Incidence of Cytomegalovirus (CMV) Disease | 0 Number of events | Standard Deviation 0 |
| Matched Unrelated Donor Stem Cell Transplant | Incidence of Cytomegalovirus (CMV) Disease | 0 Number of events | Standard Deviation 0 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Incidence of Cytomegalovirus (CMV) Disease | 0 Number of events | Standard Deviation 0 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Incidence of Cytomegalovirus (CMV) Disease | 0 Number of events | Standard Deviation 0 |
Secondary
Number of RBC Transfusions Per Subject
Average number of red blood cell (RBC) transfusion per subject
Time frame: 1 year
Population: The analyses include only those who underwent transplant
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Matched Related Donor Stem Cell Transplant | Number of RBC Transfusions Per Subject | 1.71 transfusions per person | Standard Deviation 1.79 |
| Matched Unrelated Donor Stem Cell Transplant | Number of RBC Transfusions Per Subject | 7.08 transfusions per person | Standard Deviation 12.18 |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Number of RBC Transfusions Per Subject | 4 transfusions per person | Standard Deviation 1 |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Number of RBC Transfusions Per Subject | NA transfusions per person | — |
Secondary
Participants With Established Stable Mixed Chimerism
Number of participants with myeloid chimerism of greater than 10% of donor cells at 1 year post transplant
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Matched Related Donor Stem Cell Transplant | Participants With Established Stable Mixed Chimerism | 7 Participants |
| Matched Unrelated Donor Stem Cell Transplant | Participants With Established Stable Mixed Chimerism | 30 Participants |
| Matched Unrelated Donor Stem Cell Transplant (MUD-non CGD) | Participants With Established Stable Mixed Chimerism | 3 Participants |
| Matched Unrelated Donor Transplant (MUD-CGD) Cord Blood | Participants With Established Stable Mixed Chimerism | NA Participants |